• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Phenylpyridines

Recent Advances in the Application of 4-(Pyridin-2-yl)aniline (CAS: 18471-73-3) in Chemical Biology and Pharmaceutical Research

4-(Pyridin-2-yl)aniline (CAS: 18471-73-3) is a versatile heterocyclic compound that has garnered significant attention in chemical biology and pharmaceutical research due to its unique structural features and potential applications in drug discovery. This research briefing synthesizes the latest findings on this compound, focusing on its synthetic methodologies, biological activities, and emerging therapeutic applications. Recent studies highlight its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and antimicrobial agents.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 4-(pyridin-2-yl)aniline derivatives as potent inhibitors of cyclin-dependent kinases (CDKs), with compound 7a showing IC50 values below 10 nM against CDK2 and CDK9. The research team employed structure-activity relationship (SAR) analysis to optimize the substitution pattern on both the pyridine and aniline moieties, revealing crucial insights into the pharmacophore requirements for kinase inhibition. These findings open new avenues for developing targeted cancer therapies with improved selectivity profiles.

In the field of antimicrobial research, a recent breakthrough published in Bioorganic & Medicinal Chemistry Letters (2024) reported novel 4-(pyridin-2-yl)aniline-based compounds exhibiting remarkable activity against drug-resistant Staphylococcus aureus strains. The lead compound in this series demonstrated a minimum inhibitory concentration (MIC) of 0.5 μg/mL while showing low cytotoxicity against mammalian cells. Molecular docking studies suggested that these compounds interfere with bacterial cell wall biosynthesis by targeting penicillin-binding proteins, offering a potential mechanism for overcoming β-lactam resistance.

The synthetic accessibility of 4-(pyridin-2-yl)aniline has been significantly improved through recent methodological advances. A 2023 paper in Organic Process Research & Development described a scalable, one-pot synthesis route with 85% overall yield, employing palladium-catalyzed C-N coupling as the key step. This development addresses previous challenges in large-scale production and has facilitated the compound's broader application in medicinal chemistry campaigns. The optimized protocol features mild reaction conditions, excellent functional group tolerance, and reduced metal catalyst loading, making it both economically and environmentally favorable.

Emerging applications in chemical biology have revealed the compound's utility as a fluorescent probe for monitoring enzymatic activity. Researchers at the University of Cambridge recently developed a 4-(pyridin-2-yl)aniline-derived fluorogenic substrate for real-time monitoring of cytochrome P450 activity, demonstrating superior photostability and sensitivity compared to conventional probes. This innovation, published in Chemical Science (2024), enables high-throughput screening of drug metabolism and drug-drug interactions, with potential applications in personalized medicine approaches.

In conclusion, 4-(pyridin-2-yl)aniline (CAS: 18471-73-3) continues to demonstrate remarkable versatility across multiple domains of chemical biology and pharmaceutical research. The compound's unique structural features, combined with recent synthetic and application breakthroughs, position it as a valuable scaffold for future drug discovery efforts. Ongoing research is expected to further expand its therapeutic potential, particularly in addressing unmet medical needs in oncology and infectious diseases. Future directions may include exploration of its applications in PROTAC design and as a building block for covalent inhibitors, leveraging its amine functionality for diverse conjugation strategies.

• 170850-45-0(6-(p-Tolyl)pyridin-3-amine)
• 21203-86-1(2-Phenylpyridin-4-amine)
• 126370-67-0(6-Phenyl-3-pyridinamine)
• 61102-76-9(Benzenamine, 4-(2,6-diphenyl-4-pyridinyl)-)
• 58992-84-0(4-(Isoquinolin-1-yl)aniline)
• 518982-06-4(4-(Pyridin-2-yl)aniline hydrochloride)
• 1170936-92-1(2-(3-Aminophenyl)pyridine Dihydrochloride)
• 893640-46-5(6-(m-Tolyl)pyridin-3-amine)
• 823798-56-7(Benzenamine, 4,4'-(4-[1,1'-biphenyl]-4-yl-2,6-pyridinediyl)bis-)
• 15889-32-4(3-(2-Pyridyl)aniline)